April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a ...
usfda
July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Fo...
usfda
On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after ...
usfda
On February 6, 2019, in conjunction with plasma exchange and immunosuppressive treatment, the Food and Drug Administration approved caplacizumab-yhdp (CABLIVI, Ablynx NV) for adult patients with acqui...
usfda
On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treat...
usfda
July 2021: Refer to the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe ...
usfda